An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors.
Mancini M, Gal H, Gaborit N, Mazzeo L, Romaniello D, Salame TM, Lindzen M, Mahlknecht G, Enuka Y, Burton DG, Roth L, Noronha A, Marrocco I, Adreka D, Altstadter RE, Bousquet E, Downward J, Maraver A, Krizhanovsky V, Yarden Y.
Mancini M, et al. Among authors: krizhanovsky v.
EMBO Mol Med. 2018 Feb;10(2):294-308. doi: 10.15252/emmm.201708076.
EMBO Mol Med. 2018.
PMID: 29212784
Free PMC article.